Litigation Details for ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL INC. (D.N.J. 2017)
✉ Email this page to a colleague
ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL INC. (D.N.J. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-10-31 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Esther Salas |
| Jury Demand | None | Referred To | Michael A. Hammer |
| Patents | 8,481,598 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL INC.
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL INC. (D.N.J. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-06-08 | 455 | Opinion | the three asserted patents: United States Patents No. 8,481,598 (the “’598 Patent”) and No. RE43, 879… Legal Standard A patent claim is that “portion of the patent document that defines the scope…of levomilnacipran.” ’598 Patent at 11:38–39 (emphasis added). The patent defines the terms “effective…Rather, a POSA reading the patent as a whole would understand that the patent is directed at administering…which is how the ’598 Patent refers to the dosage amounts. See, e.g., ’598 Patent at 3:11–13, 3:17–19, | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
